Skip to main content

Table 4 Clinical outcomes in crude population up to 3 years of follow-up (Kaplan-Meier estimates and log-rank p value) *

From: Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea

  EES (N = 405) R-ZES (N = 274) P value
All cause death 4.6% (16) 3.9% (9) 0.753
Cardiac death 1.7% (6) 1.7% (4) 0.962
Any myocardial infarction 2.1% (7) 1.9% (4) 0.858
 Target vessel 1.8% (6) 1.4% (3) 0.732
 Non Target vessel 0.3% (1) 0.4% (1) 0.760
 MI due to ST 1.0% (3) 1.4% (3) 0.564
Target lesion revascularization 5.6% (18) 6.6% (16) 0.333
Target vessel revascularization 7.7% (26) 8.3% (20) 0.539
Any revascularization 19.2% (54) 17.4% (37) 0.603
Target lesion failure 7.5% (25) 7.9% (19) 0.578
Patient-oriented composite outcome 22.8% (69) 20.1% (44) 0.888
Definite ST 1.3% (4) 0.9% (2) 0.789
 Acute (0–1 day) 0.0% 0.0% NA
 Subacute (2–30 days) 0.5% (2) 0.0% 0.249
 Late (31–360 days) 0.3% (1) 0.0% 0.418
 Very late (≥ 361 days) 0.5% (1) 0.9% (2) 0.296
Probable ST 0.3% (1) 0.9% (2) 0.344
 Acute (0–1 day) 0.3% (1) 0.0% 0.411
 Subacute (2–30 days) 0.0% 0.4% (1) § 0.221
 Late (31–360 days) 0.0% 0.0% NA
 Very late (≥ 361 days) 0.0% 0.5% (1) 0.215
Definite/Probable ST 1.5% (5) 1.8% (4) 0.741
  1. * Clinical outcomes were presented as cumulative incidence (Kaplan-Meier estimates, %) of primary and secondary clinical outcomes calculated. Numbers of total events are presented in parentheses. P values are log-rank p value or Breslow p value.
  2. Target lesion failure defined as a composite of cardiac death, myocardial infarction (not clearly attributed to a nontarget vessel), or clinically indicated target lesion revascularization by percutaneous or surgical methods at 3 years.
  3. Patient-oriented composite outcomes included all-cause mortality, any myocardial infarction (includes nontarget vessel territory), and any revascularization (includes all target and nontarget vessel, regardless of percutaneous or surgical methods).
  4. § Subacute stent thrombosis, presented with sudden cardiac arrest which occurred at 6 days after percutaneous coronary intervention.
  5. Abbreviations: EES everolimus-eluting stent, MI myocardial infarction, R-ZES Resolute zotarolimus eluting-stent, ST stent thrombosis, EES everolimus-eluting stent.